Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An argument for broad use of high efficacy treatments in early multiple sclerosis
James Stankiewicz, Howard L. Weiner
Neurology Neuroimmunology & Neuroinflammation (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Early versus later treatment start in multiple sclerosis: a register‐based cohort study
Thor Ameri Chalmer, Lisbeth M. Baggesen, Mette Nørgaard, et al.
European Journal of Neurology (2018) Vol. 25, Iss. 10, pp. 1262-1262
Closed Access | Times Cited: 92
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 75
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
Massimo Filippi, Romano Danesi, Tobias Derfuß, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1670-1677
Open Access | Times Cited: 67
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
B. Singer, Jenny Feng, Horacio Chiong-Rivero
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3116-3130
Open Access | Times Cited: 8
The CXCL13 index biomarker predicts success or failure of moderate-efficacy disease-modifying therapies in multiple sclerosis; a real-world study
Andrew R. Pachner, Steven C. Pike, Andrew D. Smith, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106303-106303
Closed Access | Times Cited: 1
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Amit Bar‐Or, Susan O’Brien, Michael Sweeney, et al.
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 985-997
Open Access | Times Cited: 45
Escalation vs. Early Intense Therapy in Multiple Sclerosis
Bonaventura Casanova, Carlos Quintanilla‐Bordás, Francisco Gascón
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 119-119
Open Access | Times Cited: 32
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
Tjalf Ziemssen, Douglas L. Arnold, Enríque Alvarez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis
Hans‐Peter Hartung, Sven G. Meuth, Alan J. Thompson
Multiple Sclerosis Journal (2021) Vol. 27, Iss. 10, pp. 1473-1476
Open Access | Times Cited: 28
Surveillance of drug prescribing: why outliers miss their targets – a qualitative study
Julia Gollnick, Nikoletta Zeschick, Franziska Hörbrand, et al.
BMC Health Services Research (2025) Vol. 25, Iss. 1
Open Access
Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies
Mariano Marrodán, Augusto Sao Avilés, Jordi Río, et al.
Multiple Sclerosis Journal (2025)
Closed Access
Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
Robin L. Avila, Nicole S. Croteau, Fei Tang, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
Elisabeth Gulowsen Celius, Heidi Thompson, Maija Pontaga, et al.
Patient Preference and Adherence (2021) Vol. Volume 15, pp. 15-27
Open Access | Times Cited: 25
Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis
Jennifer Massey, Katherine Jackson, Mandeep Singh, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
Niklas Frahm, David Ellenberger, Alexander Stahmann, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
Celia Oreja‐Guevara, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 3
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
Su Yeon Park, Young Nam Kwon, Sun‐Young Kim, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 10, pp. 800-805
Closed Access | Times Cited: 8
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries
Tereza Hrnčiarová, Jiří Drahota, Tim Spelman, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104803-104803
Closed Access | Times Cited: 8
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
Esther S. Frisch, Roxanne Pretzsch, Martin S. Weber
Neurotherapeutics (2021) Vol. 18, Iss. 3, pp. 1602-1622
Open Access | Times Cited: 20
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
Hans‐Peter Hartung, Sven G. Meuth, Deborah Miller, et al.
Current Opinion in Neurology (2021) Vol. 34, Iss. 4, pp. 598-603
Closed Access | Times Cited: 20
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model
Ide Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 8, pp. 1016-1025
Open Access | Times Cited: 2
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
Steffeni Papukchieva, Hyung-Do Kim, Ann-Sophie Stratil, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 88, pp. 105751-105751
Closed Access | Times Cited: 2
Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion
Renato Mantegazza, Francesco Saccà, Giovanni Antonini, et al.
Neurological Sciences (2024) Vol. 45, Iss. 12, pp. 5671-5683
Closed Access | Times Cited: 2
Autoimmune Neurogenic Dysphagia
Panos Stathopoulos, Marinos C. Dalakas
Dysphagia (2021) Vol. 37, Iss. 3, pp. 473-487
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top